• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Celgene Corporation

Celgene Corporation

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Celgene Corporation to Webcast at Upcoming Investor Conferences

    Celgene Corporation to Webcast at Upcoming Investor Conferences

  2. Celgene Corporation to Webcast at Upcoming Investor Conference

    Celgene Corporation to Webcast at Upcoming Investor Conference

  3. Celgene Announces Retirement of President and Chief Operating Officer, Jacqualyn Fouse, Ph.D. and Promotion of Scott Smith to President and Chief Operating Officer

    Celgene Announces Retirement of President and Chief Operating Officer, Jacqualyn Fouse, Ph.D. and Promotion of Scott Smith to President and Chief Operating Officer

  4. The France Foundation, American Society for Clinical Pathology, and American Society of Hematology Awarded 2017 Outstanding Live Continuing Education Activity by the Alliance for Continuing Education ...

    The France Foundation, American Society for Clinical Pathology, and American Society of Hematology Awarded 2017 Outstanding Live Continuing Education Activity by the Alliance for Continuing Education in the Health Professions

  5. Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman

    Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman

  6. UPDATE: 5 reasons to bank on biotech stocks now

    UPDATE: 5 reasons to bank on biotech stocks now

  7. Vividion Therapeutics, Inc., Launches With $50 Million Series A Financing

    Vividion Therapeutics, Inc., Launches With $50 Million Series A Financing

  8. UPDATE: 5 reasons to bank on biotech stocks now

    UPDATE: 5 reasons to bank on biotech stocks now

  9. Share Repurchase: Potential Signal of Undervaluation and Outperformance

    Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...

  10. Will the Election Affect Earnings?

    If Americans sweep Democrats into office, these healthcare proposals could get a shot in the arm. Here’s how they would have an impact on earnings.

123

©2017 Morningstar Advisor. All right reserved.